MedDataX Logo

To Demonstrate the Relative Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets

NCT ID: NCT00946790

Last Updated: 2017-03-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

1993-07-31

Study Completion Date

1993-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To demonstrate the relative bioavailability of hydroxychloroquine sulfate, 200 mg tablets.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety of Single Rising Doses and Relative Bioavailability of BI 691751

NCT01843972

Healthy
COMPLETED PHASE1

A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants

NCT04839809

Healthy Volunteers
COMPLETED PHASE1

GSK1349572 Relative Bioavailability Study

NCT01098513

Infection, Human Immunodeficiency Virus
COMPLETED PHASE1

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects

NCT03803644

Healthy Volunteer
COMPLETED PHASE1

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

NCT02034773

Healthy Volunteers
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Immunosuppression Rheumatism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)

Group Type EXPERIMENTAL

Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)

Intervention Type DRUG

2

Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)

Group Type ACTIVE_COMPARATOR

Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)

Intervention Type DRUG

Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria

* Positive test results for HIV or hepatitis B or C.
* Treatment for drug or alcohol dependence.
Minimum Eligible Age

19 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sandoz

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sandoz Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gerald Gantt, M.D.

Role: PRINCIPAL_INVESTIGATOR

PharmaKinetics Laboratories Inc.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

005-14-10551

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Phase 1 Single Dose and Multiple Ascending Dose Study to Assess the Relative Bioavailability, Food Effect, Safety, Tolerability and Pharmacokinetics of SYT-510 in Healthy Participants
NCT06670950 RECRUITING PHASE1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses and Effect of Food on the Bioavailability of BI 1060469
NCT01971502 COMPLETED PHASE1
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants
NCT05099822 TERMINATED PHASE1
Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets
NCT01366352 COMPLETED PHASE1
A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants
NCT05303220 COMPLETED PHASE1
To Evaluate the Pharmacokinetics and Safety of Oral Administration of BR9001 Compared With BR900A in Healthy Subjects
NCT03718611 COMPLETED PHASE1
Relative Bioavailability and Food Effect of SYHA1813 Oral Solution in Healthy Participants
NCT06157918 COMPLETED PHASE1
Investigation of Food Effect and Gastric ph Increase on the Bioavailability of Faldapravir
NCT01694706 COMPLETED PHASE1
A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants
NCT06941077 COMPLETED PHASE1
Bioavailability and Pharmacokinetics of BI 135585 XX Administered as Tablet With and Without Food
NCT01286571 COMPLETED PHASE1
A Study of the Safety, Tolerability, and Bioavailability of Orally Administered Venglustat in Healthy Adult Participants
NCT06418620 COMPLETED PHASE1
To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers
NCT02093819 COMPLETED PHASE1
Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.
NCT01343719 COMPLETED PHASE1
A Pharmacodynamic and Pharmacokinetic Study of RO4917838 in Healthy Volunteers
NCT01543529 COMPLETED PHASE1
A Pharmacokinetic And Bioavailability Study of Intravenous Danoprevir in Healthy Volunteers
NCT01654211 COMPLETED PHASE1
A Bioavailability and Pharmacokinetic Study of Subcutaneous and Intravenous RO6811135 in Healthy Volunteers
NCT01802853 COMPLETED PHASE1
A Study of the Relative Bioavailability of Single Dose RO4917838 and the Effect of Food in Healthy Volunteers
NCT01665976 COMPLETED PHASE1
To Demonstrate the Relative Bioavailability of Diclofenac Sodium 75 mg Enteric-Coated Tablets Under Non-Fasting Conditions
NCT00913887 COMPLETED PHASE1
Food Effect, Oral & Intravenous Pharmacokinetics and Absolute Bioavailability of BAY1834845 Including Drug-drug Interaction With Methotrexate
NCT03244462 COMPLETED PHASE1
Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809
NCT02068690 COMPLETED PHASE1
Relative Bioavailability of Sorafenib Tablet for Oral Suspension
NCT02538393 COMPLETED PHASE1
Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy Adults
NCT02860806 COMPLETED PHASE1
Glucosamine Sulfate Bioavailability
NCT06971484 COMPLETED NA
A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.
NCT04903093 COMPLETED PHASE1
BlueCQ Bioavailability
NCT00176072 COMPLETED